Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf (tacrolimus)/MMF [mycophenolate mofetil], modified release (MR) tacrolimus/MMF and Neoral (cyclosporine [ciclosporin])/MMF in de novo kidney transplant recipients.

Next Previous
X
Search
Trial Profile

A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf (tacrolimus)/MMF [mycophenolate mofetil], modified release (MR) tacrolimus/MMF and Neoral (cyclosporine [ciclosporin])/MMF in de novo kidney transplant recipients.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Ciclosporin; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 01 Apr 2009 Patient numbers amended from 638 to 668 as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 24 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top